Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The ...

Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

Speakers from across the care continuum will discuss legislative updates, glucagon-like peptide-1 (GLP-1) use for weight management, and more at this year’s AMCP Nexus.

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

The University of California, Davis today announced an expanded collaboration with the BioInnovation Institute (BII) to ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

The risk for kidney function decline is lower among new users of sodium glucose cotransporter-2 inhibitors (SGLT2i) vs glucagon-like peptide 1 receptor agonists (GLP-1RA), a real-world study of ...